Herpes Simplex Virus 2 News and Research

RSS

Herpes Simplex Virus-2 is a sexually transmitted viral infection, which often produces painful sores, usually in the genital area. Once infected, an individual may carry the virus and be subject to recurrent bouts of infection. Some estimate that as many as 20 percent of the adult population in the United States has been exposed to the virus.

AMP comments on barriers to market for molecular diagnostic tests at FDA CDRH meeting

Yesterday, the Association for Molecular Pathology (AMP) gave public comments at the FDA's Center for Devices and Radiological Health (CDRH) Council meeting on Medical Device Innovation: Barriers to Market for Molecular Diagnostic Tests.

28 Jun 2010

HSV-1 may cause cognitive deficits: Study

Exposure to the common virus that causes cold sores may be partially responsible for shrinking regions of the brain and the loss of concentration skills, memory, coordinated movement and dexterity widely seen in patients with schizophrenia, according to research led by Johns Hopkins scientists.

29 May 2010

FDA grants 510(k) market clearance for EraGen's MultiCode-RTx HSV 1&2 Kit

EraGen Biosciences Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for EraGen's MultiCode®-RTx HSV 1&2 Kit.

20 May 2010

NanoViricides signs research and development agreement with Dr. Ken S. Rosenthal's laboratory

NanoViricides, Inc., reports that it has signed a research and development agreement with Dr. Ken S. Rosenthal's laboratory at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

14 May 2010

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held May 2-6, 2010.

7 May 2010

Scientists discover human DNA that act as a traitor to body's defences

Cancer Research UK-funded scientists have discovered that stretches of human DNA act as a traitor to the body's defences by helping viruses infect people and trigger cancer-causing diseases, according to a study published in Nature Cell Biology today.

28 Apr 2010

GenVec's 2009 revenues down 8%: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

23 Apr 2010

RSCRC scientists explore mysteries of human embryonic stem cells

At Rutgers' Stem Cell Research Center scientists are exploring the mysteries of human embryonic stem cells and their potential use in treating diseases, repairing damaged organs, and drug development. Center staff also offer a course in proper lab techniques in working with stem cells.

17 Apr 2010

StockPreacher.com: GenVec's revenues for 2009 decline by 8%

StockPreacher.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

7 Apr 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

StockPreacher.com announces investment report featuring GenVec

15 Mar 2010

CDC survey finds HSV-2 infection as one of the most common STDs in U.S.

About 1 in 6 Americans (16.2 percent) between the ages of 14 and 49 is infected with herpes simplex virus type 2 (HSV-2), according to a national health survey released today by the Centers for Disease Control and Prevention. HSV-2 is a lifelong and incurable infection that can cause recurrent and painful genital sores.

10 Mar 2010

DermaGenoma releases The HerpesDX Genetic Test for Frequent Genital Herpes

Molecular dermatology research and development innovator DermaGenoma, Inc. today released The HerpesDX Genetic Test for Frequent Genital Herpes. The new screening test will help doctors assess patients’ risk for developing frequent Genital Herpes (HSV-2) outbreaks.

9 Mar 2010

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.

4 Mar 2010

Genocea Biosciences secures licensing to extensive HSV antigen patent estate

Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has licensed an extensive patent estate from the University of Washington and the Fred Hutchinson Cancer Research Center for 25 pending and issued patents related to herpes simplex virus (HSV) type 2 antigens. The addition of these patents complements the novel antigens discovered by Genocea’s unique and proprietary antigen discovery technology. The combination of Genocea’s novel intellectual property with the patent estate from the University of Washington provides the Company with a broad compendium of HSV antigen patents.

24 Feb 2010

Medivir, Meda announce agreement to commercialize Medivir’s cold sore product, Xerese

Medivir and Meda today announced an agreement for the commercialization of Medivir’s cold sore product which will be marketed in North America under the trade name Xerese™.

15 Feb 2010

Acyclovir reduces occurrence of HSV-2 genital ulcers but does not affect HIV transmission

Research from a five-year international clinical study shows that acyclovir, a commonly prescribed drug used to suppress symptoms of the herpes virus, does not affect HIV transmission by people with both viruses.

27 Jan 2010

HSV-2 can reactivate throughout the genital tract

Genital herpes caused by a reactivation of herpes simplex virus type 2 (HSV-2) is generally treated as a lesion in one specific area of the genital region. A new study, however, finds that the virus can frequently reactivate throughout the genital tract, an important new concept that could help guide both HSV-2 treatment and prevention.

23 Jan 2010

New study indicates viruses employ a novel mechanism to spread more quickly than thought possible

New video footage of a virus infecting cells is challenging what researchers have long believed about how viruses spread, suggesting that scientists may be able to create new drugs to tackle some viruses.

22 Jan 2010

Researchers explain how HSV dismantles host's defense systems

A viral infection is like an uninvited, tenacious houseguest in the cell, using a range of tricks to prevent its eviction. Researchers at the Salk Institute for Biological Studies have identified one of the key proteins allowing herpes simplex virus (HSV) DNA to fly under the radar of their hosts' involuntary hospitality.

21 Jan 2010